Xyall

Xyall is a medtech company based in Eindhoven, The Netherlands, founded in 2018 by Guido du Pree and Hans van Wijngaarden. The company specializes in developing fully automated, high-precision tissue dissection solutions aimed at enhancing molecular diagnostic testing, particularly in precision oncology. Their flagship product, the Tissector High Throughput (HT) system, is the first automated platform for high-volume tissue dissection. This system allows molecular diagnostic laboratories to perform tissue dissection more quickly and accurately than traditional manual methods. The Tissector HT system meets the increasing demand for high-quality tissue samples needed for advanced molecular tests, which are essential for personalized cancer therapies. Xyall's technology combines precision robotics, digital pathology, and workflow optimization to provide standardized and scalable solutions for tissue macro-dissection. Xyall serves large molecular diagnostic laboratories and clinical pathology labs that require automated tissue dissection platforms. The company is also collaborating with digital pathology innovators to improve workflow and image management in molecular pathology testing.

• Employees 19
• Founded 2018
• Total Funding $11961590